Compare PMTS & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | MCRB |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.4M | 139.7M |
| IPO Year | 2015 | 2015 |
| Metric | PMTS | MCRB |
|---|---|---|
| Price | $16.05 | $8.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $27.67 | $14.33 |
| AVG Volume (30 Days) | 81.5K | ★ 88.7K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | 1.25 | ★ 2.40 |
| Revenue | ★ $312,189,000.00 | $126,325,000.00 |
| Revenue This Year | $9.09 | N/A |
| Revenue Next Year | $6.79 | N/A |
| P/E Ratio | $12.56 | ★ $3.73 |
| Revenue Growth | 12.27 | ★ 1672.24 |
| 52 Week Low | $10.81 | $0.36 |
| 52 Week High | $30.51 | $29.98 |
| Indicator | PMTS | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 64.36 | 36.34 |
| Support Level | $13.84 | $6.99 |
| Resistance Level | $16.38 | $16.14 |
| Average True Range (ATR) | 1.01 | 0.53 |
| MACD | 0.48 | 0.24 |
| Stochastic Oscillator | 67.45 | 53.87 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.